Browser storage is unavailable. Keep this page open and export your collection before leaving.
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology. Viruses, ticks, and worms have experimented over millions of years to create proteins that control the human immune system. We use AI to identify these proteins and engineer them into next-generation autoimmune therapies.
Our team is three PhD scientists from UCSF, UCSD, and UC Berkeley who have worked together for 3+ years in biotech. We have deep expertise in parasite biology, computational biology, and software for AI-based protein structure prediction
Scientist and operator transforming natural proteins into therapies. Trained in evolutionary and developmental biology at Harvard (AB) and UC Berkeley (PhD). Previously led software teams, product development, and scientific partnerships as Chief of Staff at a $500M biotech. Now building a platform to mine proteins from viruses, ticks, and worms that will become the next blockbuster drugs for autoimmune disease.
Entrepreneurial scientist using evolution to build the next generation of therapeutics for autoimmune disease. UCSF-trained PhD with expertise spanning parasitology, virology, and genomics. Published over 50 scientific papers, and is a coinventor on a patent for anti-CRISPR proteins. Former Miller Fellow at UC Berkeley, and previously led a venture creation team at an early stage biotech company. Motivated by a lifelong fascination with parasites.
I'm a molecular and computational biologist working to revolutionize drug discovery for autoimmune disease. At Ditto, I lead the platform for engineering parasite-derived therapeutics. I hold a PhD in microbiology, genomics, and plant genetics, with a focus on sequencing, high-throughput screening, and computational pipeline development. Published in Nature Microbiology and eLife. Previously at Illumina, DuPont, and an early-stage biotech venture team.
Founded 2025 · Source
Source-based assessment · automated evidence rules
The retained text does not establish product availability or customer use.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.
abinitio bio is the AI-native operating platform for drug development and manufacturing.
Founders · Product · How it works
Same category · Biotech pharma
Our autonomous biodefense capabilities ensure validated point-of-care diagnostics for emerging biological threats are developed in days, not 12+ months.
Founders
Same category · Biotech pharma
Anthrogen is engineering post-modality biology. Today's modalities reflect historical contingencies in biological progress, not fundamental categories. We develop the AI systems that design modular biological machines and the…
Founders · Product
Same category · Biotech pharma
Anto is building a foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving…
Founders · Product
Same category · Biotech pharma
Generative AI Medical Writing Solution for Biotech, Life Sciences, Pharma & Medical Devices | Artos AI. Book a demo online.
Customers · Founders · Product
Same category · Biotech pharma
Astraea is AI software for clinical trial teams. Build SDTM, ADaM and TFL outputs in your environment, with qualified experts reviewing every output.
Founders · Product · How it works
Same category · Biotech pharma
